Ensifentrine is a novel, potent, and selective dual inhibitor of phosphodiesterase (PDE) 3
and PDE4 designed for delivery by inhalation that combines effects on airway inflammation …

Rationale: Ensifentrine is a novel, selective, dual phosphodiesterase (PDE) 3 and PDE4
inhibitor with bronchodilator and antiinflammatory effects. Replicate phase III trials of …

Introduction Ensifentrine is an inhaled first-in-class dual inhibitor of phosphodiesterase
(PDE) 3 and 4. In a four-week randomized, double-blind, placebo-controlled, parallel-group …

Background Many patients with chronic obstructive pulmonary disease (COPD) still
experience daily symptoms, exacerbations, and accelerated lung function decline, even …

Ensifentrine (RPL554), an inhaled 'bifunctional'dual phosphodiesterase 3/4 inhibitor that
exhibits both bronchodilator and anti-inflammatory activities, provides a new option in the …

Current pharmacological treatments for chronic obstructive pulmonary disease (COPD) are
mostly limited to inhaled bronchodilators and corticosteroids. Azithromycin can contribute to …

Purpose Ensifentrine is an inhaled dual inhibitor of phosphodiesterase (PDE) 3 and 4 that
has shown bronchodilatory effects and symptom improvement in clinical studies in patients …

Introduction: A compound that simultaneously inhibits PDE3 and PDE4 should increase
airway caliber by relaxing the smooth muscle and, simultaneously, suppress airway …

Phosphodiesterase (PDE) 4 inhibitors prevent the metabolism of cyclic adenosine
monophosphate, thereby reducing inflammation. Inhaled PDE4 inhibitors aim to restrict …

Phosphodiesterase enzymes (PDE) have long been known as regulators of cAMP and
cGMP, second messengers involved in various signaling pathways and expressed in a …